top of page
  • Writer's pictureFutureMeds

FutureMeds Appoints Iwona Tongbhoyai as Vice President of Operations

Updated: Jan 24, 2023

FutureMeds has appointed Iwona Tongbhoyai as Vice President of Operations. She will be responsible for the management and oversight of the operations of FutureMeds’ growing dedicated research site network.

With over 12 years Sites and Clinical Trials Management experience and over 7 years Business Consultancy experience, Iwona Tongbhoyai will play a key role in increasing FutureMeds’ operational efficiency and strengthening the FutureMeds brand by providing successful and effective solutions to clients, partners and patients alike.

“I am so happy to have Iwona back at my side. Her energy, optimism, passion and industry know-how will be a huge support for FutureMeds’ growth aspirations. Our recent success is setting the path forward to create an unprecedented opportunity for patients to participate in clinical research. Iwona will be a great support for our executive team in building our site network.”

- Dr. Radoslaw Janiak, CEO of FutureMeds

Throughout the last 6 years at Accelerated Enrolment Solutions (previously known as Synexus and now part of PPD) Iwona was responsible for the Western Europe Region where she delivered site and study solutions across AES’ 14 sites in the region. She successfully led the Sites and Patients Feasibility, and New Solutions teams, improving the efficiency of the global startup, and clinical trial and site operational readiness.

Given the growing complexity of trials, clinical trial and site operational readiness is becoming an increasingly important factor for sponsors and clients. Clinical trial and site operational readiness mitigates the risk of severe delays in site identification, initiation and patient enrollment, decreases procedural errors related to randomization, dosing, or protocol procedure implementation, and enables project team leaders to better anticipate team performance.

As site operational readiness is critical to delivering trials that run smoothly, remain compliant, and stay within budget, Iwona will focus on further improving FutureMeds’ performance in this area. Using her passion and dedication for trials and site management she aims to raise the standards of FutureMeds’ dedicated research sites by training and better preparing teams, whilst also enhancing the capabilities for running decentralized trials. Compared to the traditional model, dedicated clinical trial sites and teams are more likely to recruit and retain patients, provide better patient experiences, avoid protocol deviations, and meet deadlines.

Besides clinical trial and site operational readiness, Iwona aims to forge closer ties with global trial and cross-country trial sponsors to help them create tailored trial solutions that comply with regulatory guidance across the target countries, catering for cross-border data standards, localisation and retention rules.

By increasing sponsor collaboration with Site Management Organizations such as FutureMeds at the planning stage of new trials, sponsors are better able to account for complexities in the trial-design planning process and therefore decrease the historically long cycle times in clinical trials.

“I am thrilled to join FutureMeds and use my knowledge and experience to support them on their exciting journey. I am looking forward to working with such a great, dynamic team. Helping them grow and expand across Europe and delivering effective and innovative solutions for our clients, patients and clinical research partners are my top priorities in the coming years.“ commented Iwona Tongbhoyai, Vice President of Operations at FutureMeds.

FutureMeds, the fast-growing independent Site Management Organization that currently operates 12 sites across 4 countries, is already in the top tier of Dedicated Research Site Networks in Europe.

About FutureMeds

FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.

FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.

Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.

Follow us on LinkedIn

Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.


Commenting has been turned off.
bottom of page